ESCONDIDO, CA/ ACCESSWIRE/ March 16, 2021/ CB Scientific. Inc. (OTC PINK:CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces today the anticipated addition of three major hospital chains to use Remote Cardiac Monitoring Services in Thailand using the proprietary my-Cam device and associated cloud-based software portal through their exclusive authorized distributor Mango Wellness Co., Ltd. (MWC).

Mango Wellness Co., Ltd., due to the successful on-site trial evaluations of our innovative my-Cam monitor and my-Cardia software portal in two regions of Thailand, has come to a formal agreement to provide Remote Cardiac Monitoring Services to three major hospital chains. Ramkhamhaeng Hospital (one of the five largest private hospital groups in Thailand consisting of 40 hospitals), Bangkok Hospital Nakon Ratchasima (one of the largest hospitals in NE Thailand), and Bangpakok9 Hospital have all agreed to offer my-Cam services through MWC to their physicians and associated patients beginning in April 2021. Mango Wellness Co., Ltd. and their subsidiary My-Cardia Thailand, in further efforts to expand their product offering, continue trials of the my-Cam device, which today consist of 102 cardiologists in 42 hospitals totaling more than 1700 ambulatory remote cardiac event monitoring tests to date since the beginning of the year. As apart of these trials, MWC is also in negotiations with N Health Services, a purchasing subsidiary of Bangkok Dusit Medical Services (BDMS – one of the most prestigious hospital networks in the Asia-Pacific region), to secure a joint marketing partnership to promote MWC’s Remote Cardiac Monitoring Services to the 48 hospitals in the BDMS network in Thailand.

“Mango Wellness is very pleased with how well the my-Cam device has performed and has been received throughout this introductory trial period in our country. With a diagnostic success rate of 85%, including endorsements from several electrophysiologists and cardiologists as part of these successful trials, I remain extremely optimistic about the tremendous potential of the Remote Cardiac Monitoring market in Thailand. During this test period, we received a testimonial from one of our trial physicians, Dr. Sura Boonrat of the Central Chest Institute of Thailand. Using the my-Cam device, he was able to capture a cardiac event, which he called a ‘pause’, that occurred three times in one of his patients, who was transported to the hospital where he passed out. The detection of the ‘pause’ led to the doctor implanting a pacemaker that day. In the words of the physician, and the patient, using the my-Cam device saved his life. This just further proves that using this alternative approach in Thailand can only help to advance the earlier detection of problematic cardiac rhythms in Thailand resulting in improved quality of life for patients here with potential heart issues, just as it did for Dr. Boonrat’s patient.” said Joe Chan, managing director for Mango Wellness and My-Cardia Thailand.

Further penetration of the remote cardiac monitoring market into government hospitals and medical universities in Thailand continues, including Chulalongkorn, Siriraj, Rajavithi, Police General, and Phramongkutklao, to name a few.

CB Scientific plans to make further announcements to keep its shareholders, industry participants, and the public markets informed through press releases and regulatory filings as new developments occur. 

CB Scientific, Inc. Company Contact Information: 

340 State Place 
Escondido, CA 92029 

Telephone number: 
(888) 225-0870

Emails: 
General inquires: info@cbscientificinc.com 
Investor Inquiries: investor@cbscientificinc.com

Company Social Media Outlets: 
Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

Mango Wellness Co., Ltd./My-Cardia Thailand Co., Ltd. Company Contact Information: 

Mango Wellness Co., Ltd.
Glas Haus Building, Level P, Unit PO1
1 Sukhumvit 25, North Klongtoey
Wattana, Bangkok, Thailand 10110

My-Cardia Thailand Co., Ltd.
190 Sutthisan Road, Intersection 1
Ratchadaphisek, Dindaeng
Bangkok, Thailand 10400

Telephone number: 
+66 (0) 21015576 – Mango Wellness
+66 (0) 971566481 – My-Cardia Thailand

Emails: 
General inquires: info@mangowellnessthailand.com
General inquires: info@mycardiathailand.com

Company Website and Social Media Outlets: 
Mango Wellness Thailand website, Twitter, Facebook, Instagram and YouTube
My-Cardia Thailand website, Facebook and YouTube

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE: CB Scientific, Inc.